BioSyent Pharma Receives Health Canada Approval to Market New Urgent Care Product
June 12 2014 - 8:00AM
Marketwired
BioSyent Pharma Receives Health Canada Approval to Market New
Urgent Care Product
TORONTO, ONTARIO--(Marketwired - Jun 12, 2014) - BioSyent Inc.
("BioSyent") (TSX-VENTURE:RX) is pleased to announce that its
subsidiary BioSyent Pharma Inc. has received Health Canada -
Therapeutics Products Directorate approval to market a new urgent
care product. This is the first of two products that were
in-licensed from a European partner and submitted to Health Canada
in 2013 for approval.
The newly approved urgent care drug is supplied in a patented
delivery system that offers technical advantages over existing
alternatives and will be used in hospitals and acute care settings.
These products will provide hospitals, clinics, and healthcare
professionals with improved patient safety as well as operational
efficiencies and will be marketed by BioSyent Pharma's Hospital
Division. It is anticipated that this new product will be launched
in late 2014 or early 2015. "In anticipation of Health Canada
approval our commercial team has started the launch preparation
process for this new product," said René Goehrum, President and CEO
of BioSyent. "We have already started discussions with key opinion
leaders and other decision makers in the Canadian hospital market."
Further product details will be disclosed closer to the launch
date.
For a direct market quote (15 minutes delay) for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
About BioSyent Inc.
Listed on the Toronto Venture Exchange under the trading symbol
"RX", BioSyent is a profitable growth oriented specialty
pharmaceutical company which searches the globe to in-license or
acquire innovative pharmaceutical products that have been
successfully developed, are safe and effective, and have a proven
track record of improving the lives of patients and supporting the
healthcare professionals that treat them.
Once a product of interest has been found, BioSyent then
acquires the exclusive rights to the product and manages it through
the Canadian governmental regulatory approval process. Once
approved, BioSyent markets the product throughout Canada.
At the date of this press release the Company had 13,801,195
shares issued and outstanding.
This press release may contain information or statements
that are forward-looking. The contents herein represent our
judgment, as at the release date, and are subject to risks and
uncertainties that may cause actual results or outcomes to be
materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to,
those associated with clinical trials, product development, future
revenue, operations, profitability and obtaining regulatory
approvals.
The TSX
Venture Exchange assumes no responsibility for the accuracy of this
release and neither approves nor disapproves of the same.
BioSyent Inc.Mr. Rene C. GoehrumPresident and CEO(905)
206-0013investors@biosyent.comwww.biosyent.com
Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2023 to Jul 2024